Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fumaderm for therapy-resistant alopecia areata
2011-000659-18Phase 2Active
- Sponsor
- University Hospital Tübingen
- Start
- Jun 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Fumaderm and Fumaderm initial in alopecia areata, sponsored by University Hospital Tübingen. Primary endpoint: Average improvement in SALT score. Started Jun 2011; status: active.
02
Drugs
FumadermFumaderm initial
03
Conditions
alopecia areata
Beyond the preview
Go deeper on 2011-000659-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-000659-18.